Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CINDY E OWEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1598803819
CMS profile
117868
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,019.13

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,019.13 72

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CINDY E OWEN

NPI 1598803819 · CMS profile ID 117868

Allopathic & Osteopathic Physicians / Dermatology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 72 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598803819?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $1,019.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $13.2512/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887417031 CMS
ABBVIE INC. $6.4812/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297873 CMS
Lilly USA, LLC $6.1512/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954257 CMS
ABBVIE INC. $16.5811/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297871 CMS
Lilly USA, LLC $6.1611/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917952635 CMS
Janssen Biotech, Inc. $1.8511/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934677 CMS
Regeneron Healthcare Solutions, Inc. $27.2311/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927310077 CMS
ABBVIE INC. $14.9211/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297869 CMS
Novartis Pharmaceuticals Corporation $24.1810/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894049523 CMS
Lilly USA, LLC $5.7510/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954411 CMS
ABBVIE INC. $5.2210/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297867 CMS
GENZYME CORPORATION $22.6210/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002447 CMS
ABBVIE INC. $24.6010/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297865 CMS
Regeneron Healthcare Solutions, Inc. $24.5009/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927310073 CMS
ABBVIE INC. $4.9109/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297863 CMS
Lilly USA, LLC $6.3709/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917952287 CMS
ABBVIE INC. $11.1309/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297861 CMS
ABBVIE INC. $14.8409/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297859 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.9308/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887417033 CMS
ABBVIE INC. $5.6208/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297857 CMS
GENZYME CORPORATION $29.3708/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002421 CMS
ABBVIE INC. $14.7408/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297855 CMS
ABBVIE INC. $16.6808/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297853 CMS
Janssen Biotech, Inc. $1.3308/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934703 CMS
Janssen Biotech, Inc. $23.0808/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934709 CMS
Lilly USA, LLC $6.3508/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954255 CMS
Lilly USA, LLC $5.2508/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917950217 CMS
Regeneron Healthcare Solutions, Inc. $23.2508/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927310067 CMS
ABBVIE INC. $19.0407/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297851 CMS
GENZYME CORPORATION $23.2807/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002403 CMS
Janssen Biotech, Inc. $16.1507/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934687 CMS
ABBVIE INC. $10.8707/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297849 CMS
ABBVIE INC. $5.2407/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297847 CMS
ABBVIE INC. $5.1907/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297845 CMS
Lilly USA, LLC $19.2207/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954991 CMS
Janssen Biotech, Inc. $4.2306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934681 CMS
Janssen Biotech, Inc. $16.5406/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934693 CMS
Janssen Biotech, Inc. $20.1606/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934699 CMS
ABBVIE INC. $4.9106/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297843 CMS
ABBVIE INC. $5.6805/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297841 CMS
Lilly USA, LLC $12.3905/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917952633 CMS
Janssen Biotech, Inc. $18.0905/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934715 CMS
Novartis Pharmaceuticals Corporation $21.1305/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894049519 CMS
ABBVIE INC. $7.9305/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297839 CMS
ABBVIE INC. $18.6405/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297837 CMS
ABBVIE INC. $19.1304/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891297835 CMS
GENZYME CORPORATION $23.6804/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939002377 CMS
Lilly USA, LLC $5.2604/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917954409 CMS
Janssen Biotech, Inc. $17.4304/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934641 CMS
Janssen Biotech, Inc. $23.8504/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885934647 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,410.66 70
PY2020 $4,329.13 26
PY2021 $1,014.27 67
PY2022 $1,019.13 72
PY2023 $883.07 50
PY2024 $1,269.36 78
PY2025 $1,140.98 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $848,779.58 205
PY2024 Principal investigator $465,404.25 284
PY2023 Principal investigator $512,761.61 145
PY2022 Recipient $8.00 1
PY2022 Principal investigator $318,333.10 76
PY2021 Recipient $579.11 2
PY2021 Principal investigator $303,603.63 109
PY2020 Recipient $5,811.05 7
PY2020 Principal investigator $509,738.55 72
PY2019 Recipient $47,562.83 13
PY2019 Principal investigator $1,244,974.63 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,000.00 12/24/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434323
Principal investigator 1 Incyte Corporation $1,358.50 12/22/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525982
Principal investigator 1 Janssen Research & Development, LLC $1,100.00 12/22/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436240
Principal investigator 1 Janssen Research & Development, LLC $468.00 12/22/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436247
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 12/22/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436284
Principal investigator 1 SANOFI US SERVICES INC. $263.90 12/17/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104384
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,565.00 12/11/2025 Non-covered Recipient Entity
DS Research of Kentucky, LLC
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797012
Principal investigator 1 Incyte Corporation $1,782.10 12/08/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526000
Principal investigator 1 ABBVIE INC. $49,826.85 12/04/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202528796
Principal investigator 1 ABBVIE INC. $5,100.00 12/04/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202528798
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525971
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525975
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525978
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525991
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526004
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526008
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526012
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526016
Principal investigator 1 Incyte Corporation $22.90 12/01/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526019
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,595.05 12/01/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289025
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,841.60 11/26/2025 Non-covered Recipient Entity
DS Research of Kentucky
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051553
Principal investigator 1 Incyte Corporation $1,234.80 11/24/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525987
Principal investigator 1 SANOFI US SERVICES INC. $2,919.80 11/14/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104379
Principal investigator 1 ABBVIE INC. $9,888.00 11/13/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524065
Principal investigator 1 ABBVIE INC. $1,000.00 11/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523823
Principal investigator 1 ABBVIE INC. $1,500.00 11/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523825
Principal investigator 1 ABBVIE INC. $2,500.00 11/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523829
Principal investigator 1 ABBVIE INC. $1,540.00 11/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523831
Principal investigator 1 ABBVIE INC. $2,500.00 11/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523833
Principal investigator 1 ABBVIE INC. $2,000.00 11/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202523835
Principal investigator 1 SANOFI US SERVICES INC. $2,366.65 11/12/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104366
Principal investigator 1 ABBVIE INC. $45,297.00 11/05/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521745
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,337.47 10/28/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190310450
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,248.60 10/27/2025 Non-covered Recipient Entity
DS Research of Kentucky
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051551
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,742.55 10/22/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287263
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,416.20 10/10/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434319
Principal investigator 1 ABBVIE INC. $20,435.85 10/09/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515987
Principal investigator 1 Incyte Corporation $1,885.50 10/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525995
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,280.00 09/30/2025 Non-covered Recipient Entity
DS Research of Kentucky
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,482.65 09/26/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285989
Principal investigator 1 SANOFI US SERVICES INC. $4,119.05 09/24/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104301
Principal investigator 1 SANOFI US SERVICES INC. $275.60 09/24/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104307
Principal investigator 1 ABBVIE INC. $4,650.00 09/22/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202511786
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,524.80 09/17/2025 Non-covered Recipient Entity
DS Research of Kentucky
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051549
Principal investigator 1 ABBVIE INC. $500.00 09/16/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511058
Principal investigator 1 ABBVIE INC. $857.82 09/16/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202511060
Principal investigator 1 Incyte Corporation $1,000.00 09/12/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240527085
Principal investigator 1 Incyte Corporation $500.00 09/12/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240527090
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 09/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 09/12/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285369
Principal investigator 1 ABBVIE INC. $145.84 09/11/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510772
Principal investigator 1 ABBVIE INC. $4,641.00 09/11/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510774
Principal investigator 1 ABBVIE INC. $500.00 09/09/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202510346
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,498.40 09/08/2025 Non-covered Recipient Entity
DS Research of Kentucky
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051547
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,248.00 09/08/2025 Non-covered Recipient Entity
DS Research of Kentucky
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051561
Principal investigator 1 ABBVIE INC. $40,579.50 09/04/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509666
Principal investigator 1 Incyte Corporation $250.00 09/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240527094
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,625.80 09/03/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285043
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,200.00 09/02/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434313
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,000.00 09/02/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434316
Principal investigator 1 Janssen Research & Development, LLC $2,250.00 08/25/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436264
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $625.00 08/21/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434309
Principal investigator 1 SANOFI US SERVICES INC. $10,739.95 08/20/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104296
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,624.73 08/14/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284295
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,251.20 08/07/2025 Non-covered Recipient Entity
DS Research of Kentucky
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051545
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,064.00 08/07/2025 Non-covered Recipient Entity
DS Research of Kentucky
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051559
Principal investigator 1 ABBVIE INC. $42,129.00 08/06/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202502991
Principal investigator 1 Janssen Research & Development, LLC $1,905.00 08/01/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436290
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,088.85 08/01/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,792.15 08/01/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283661
Principal investigator 1 Incyte Corporation $1,234.80 07/18/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525967
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,306.70 07/18/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434304
Principal investigator 1 Eli Lilly and Company $750.00 07/08/2025 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187889052
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,762.10 07/08/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282408
Principal investigator 1 ABBVIE INC. $18,400.50 07/02/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202494391
Principal investigator 1 SANOFI US SERVICES INC. $2,291.25 07/02/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104290
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,816.00 06/23/2025 Non-covered Recipient Entity
DS Research of Kentucky
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051557
Principal investigator 1 Incyte Corporation $3,000.00 06/18/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525853
Principal investigator 1 Incyte Corporation $500.00 06/18/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525874
Principal investigator 1 Incyte Corporation $500.00 06/18/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525900
Principal investigator 1 SANOFI US SERVICES INC. $6,722.30 06/13/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104214
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,194.60 06/04/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280734
Principal investigator 1 ABBVIE INC. $840.00 06/03/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489497
Principal investigator 1 Incyte Corporation $13.39 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525890
Principal investigator 1 Incyte Corporation $5.30 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525909
Principal investigator 1 Incyte Corporation $49.36 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525913
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525916
Principal investigator 1 Incyte Corporation $45.80 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525920
Principal investigator 1 Incyte Corporation $15.45 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525925
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525949
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525954
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525958
Principal investigator 1 Janssen Research & Development, LLC $2,475.00 05/26/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436269
Principal investigator 1 Incyte Corporation $1,332.00 05/21/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,416.89 05/20/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279972
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,782.42 05/09/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434301
Principal investigator 1 ABBVIE INC. $32,020.50 05/07/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483199
Principal investigator 1 Incyte Corporation $1,372.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525850
Principal investigator 1 Incyte Corporation $2,224.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525856
Principal investigator 1 Incyte Corporation $221.80 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525859
Principal investigator 1 Incyte Corporation $361.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525870
Principal investigator 1 Incyte Corporation $361.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525896
Principal investigator 1 Incyte Corporation $1,480.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525929
Principal investigator 1 Incyte Corporation $1,480.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525933
Principal investigator 1 Incyte Corporation $1,480.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525937
Principal investigator 1 Incyte Corporation $1,372.00 05/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525945
Principal investigator 1 SANOFI US SERVICES INC. $25,571.65 05/02/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104203
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,000.00 05/01/2025 Non-covered Recipient Entity
DS Research of Kentucky
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo No dispute reported 06/30/2026 1244051543
Principal investigator 1 Amgen Inc. $30,130.00 04/23/2025 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DS RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648075
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,004.85 04/11/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277986
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,680.70 04/08/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434292
Principal investigator 1 ABBVIE INC. $23,239.50 04/03/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202472600
Principal investigator 1 Incyte Corporation $80.15 04/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525878
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525882
Principal investigator 1 Incyte Corporation $3,200.00 04/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525886
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525905
Principal investigator 1 Incyte Corporation $8.24 04/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525941
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525962
Principal investigator 1 Amgen Inc. $8,600.00 03/22/2025 Non-covered Recipient Entity
DS RESEARCH
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246640889
Principal investigator 1 Incyte Corporation $9,000.00 03/20/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240527075
Principal investigator 1 Incyte Corporation $500.00 03/20/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240527080
Principal investigator 1 Incyte Corporation $1,872.00 03/12/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525640
Principal investigator 1 Eli Lilly and Company $1,230.27 03/10/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187882352
Principal investigator 1 ABBVIE INC. $75.00 03/07/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202459082
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,704.38 03/04/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275937
Principal investigator 1 Incyte Corporation $186.81 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525729
Principal investigator 1 Incyte Corporation $4.24 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525733
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525737
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525742
Principal investigator 1 Incyte Corporation $4.86 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525745
Principal investigator 1 Incyte Corporation $0.62 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525750
Principal investigator 1 Incyte Corporation $0.62 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525755
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525759
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525762
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525765
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525793
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525800
Principal investigator 1 Incyte Corporation $4.86 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525804
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525812
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525816
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525820
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525824
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525827
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525831
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525835
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525841
Principal investigator 1 Janssen Research & Development, LLC $1,460.00 03/03/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436253
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 02/26/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104136
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 02/26/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104141
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,459.95 02/26/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275571
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 02/21/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104120
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/21/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104125
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/21/2025 Non-covered Recipient Entity
Ds Research Of Kentucky, Llc
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226104132
Principal investigator 1 Eli Lilly and Company $8,876.00 02/12/2025 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187889050
Principal investigator 1 Janssen Research & Development, LLC $2,061.00 02/07/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436259
Principal investigator 1 ABBVIE INC. $8,085.00 02/06/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202446719
Principal investigator 1 Janssen Research & Development, LLC $13,870.00 02/03/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175436276
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $16,605.90 02/03/2025 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246434287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 02/03/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274601
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,250.00 01/29/2025 Non-covered Recipient Entity
DS Research of Kentucky
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1244051555
Principal investigator 1 SANOFI US SERVICES INC. $880.00 01/27/2025 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226112184
Principal investigator 1 Incyte Corporation $6,000.00 01/24/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525628
Principal investigator 1 Incyte Corporation $1,000.00 01/24/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525631
Principal investigator 1 SANOFI US SERVICES INC. $2,800.00 01/24/2025 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1226112190
Principal investigator 1 Amgen Inc. $13,798.81 01/21/2025 Non-covered Recipient Entity
DS RESEARCH
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,303.10 01/21/2025 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274261
Principal investigator 1 Incyte Corporation $1,329.30 01/15/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525636
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,144.21 01/10/2025 Non-covered Recipient Entity
Dermatology Specialists Research
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235997691
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525624
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525645
Principal investigator 1 Incyte Corporation $286.20 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525649
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525654
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525658
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525662
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525667
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525672
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525677
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525681
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525685
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525689
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525693
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525697
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525701
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525706
Principal investigator 1 Incyte Corporation $48.54 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525710
Principal investigator 1 Incyte Corporation $62.27 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525714
Principal investigator 1 Incyte Corporation $0.93 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525718
Principal investigator 1 Incyte Corporation $9.72 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525723
Principal investigator 1 Incyte Corporation $24.68 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525726
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525769
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525772
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525776
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525781
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525785
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525787
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525790
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525808
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240525846
Principal investigator 1 Incyte Corporation $541.60 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617160
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617164
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617168
Principal investigator 1 Incyte Corporation $24.68 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617172
Principal investigator 1 Incyte Corporation $0.31 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617176
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617179
Principal investigator 1 Incyte Corporation $8.22 01/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240617183